



# Seoul International Digestive Disease Symposium 2024

In Conjunction with the Annual Meeting of the Korean Society of Gastroenterology

April 20-21, 2024  
Grand Walkerhill Seoul, Korea

*"Pioneering the future of digestive diseases"*



SIDDS 2024

<b>Name</b>	ZEV A. WAINBERG, M.D.
<b>Affiliation</b>	University of California Los Angeles
<b>Country</b>	USA

<b>Educational Background</b>	
B.A. McGill University	05/1995
M.Sc. McGill University	01/1997
M.D. Sackler School of Medicine, Tel Aviv University	05/2000
Internship, Internal Medicine Montefiore Medical Center Albert Einstein College of Medicine	2000-2001
Residency, Internal Medicine Montefiore Medical Center Albert Einstein College of Medicine	2001-2003
Fellowship, Hematology/Oncology David Geffen School of Medicine at UCLA	2003-2006

<b>Professional Experience</b>	
<b>Present positions</b>	
Health Sciences Clinical Professor of Medicine and Surgery Co-Director, GI Oncology Program Division of Hematology-Oncology David Geffen School of Medicine at UCLA	2020-present
Medical Director, Pancreas Cancer Research Program David Geffen School of Medicine at UCLA	2016-present
Director, Early Phase Clinical Research Program Jonsson Comprehensive Cancer Center (JCCC) David Geffen School of Medicine at UCLA	2012-present
Medical Director, Colorectal Cancer Center David Geffen School of Medicine at UCLA	2011-present
Medical Director, Upper GI Cancer Center	2019-Present



# Seoul International Digestive Disease Symposium 2024

In Conjunction with the Annual Meeting of the Korean Society of Gastroenterology

April 20-21, 2024  
Grand Walkerhill Seoul, Korea

*"Pioneering the future of digestive diseases"*



SIDDS 2024

## Previous positions

Health Sciences Clinical Instructor Division of Hematology/Oncology, Department of Medicine David Geffen School of Medicine at UCLA	2006-2008
Health Sciences Assistant Clinical Professor of Medicine Co-Director, GI Oncology Program Division of Hematology/Oncology, Department of Medicine David Geffen School of Medicine at UCLA	2008-2014
Associate Clinical Professor of Medicine and Surgery Co-Director, GI Oncology Program Division of Hematology-Oncology David Geffen School of Medicine at UCLA	2014-2020

## Main Scientific Publications

- Epistola R, Sperandio R, **Wainberg Z**, Iqbal S, Chao J. Role of PD-1 Inhibitors in the Treatment of Esophagogastric Adenocarcinoma: Patient Selection and Reported Outcomes. *Cancer Manag Res.* 2023 Mar 18;15:265-275. doi: 10.2147/CMAR.S341468. eCollection 2023.PMID: 36969544
- Nimgaonkar V, Krishna V, Krishna V, Tiu E, Joshi A, Vrabac D, Bhambhani H, Smith K, Johansen JS, Makawita S, Musher B, Mehta A, Hendifar A, **Wainberg Z**, Sohal D, Fountzilias C, Singhi A, Rajpurkar P, Collisson EA. Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment outcomes in pancreatic cancer. *Cell Rep Med.* 2023 Apr 18;4(4):101013. doi: 10.1016/j.xcrm.2023.101013. Epub 2023 Apr 11.PMID: 37044094
- Ogata T, Narita Y, **Wainberg ZA**, Van Cutsem E, Yamaguchi K, Piao Y, Zhao Y, Peterson PM, Wijayawardana SR, Abada P, Chatterjee A, Muro K. Exploratory Analysis of Patients With Gastric/Gastroesophageal Junction Adenocarcinoma With or Without Liver Metastasis From the Phase 3 RAINBOW Study. *J Gastric Cancer.* 2023 Apr;23(2):289-302.doi:0.5230/jgc.2023.23.e15.PMID: 37129153
- Yoshino T, Di Bartolomeo M, Raghav K, Masuishi T, Loupakis F, Kawakami H, Yamaguchi K, Nishina T, **Wainberg Z**, Elez E, Rodriguez J, Fakih M, Ciardiello F, Saxena K, Kobayashi K, Bako E, Okuda Y, Meinhardt G, Grothey A, Siena S; DESTINY-CRC01 investigators. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer. *Nat Commun.* 2023 Jun 7;14(1):3332. doi: 10.1038/s41467-023-38032-4.





- Van Cutsem E, di Bartolomeo M, Smyth E, Chau I, Park H, Siena S, Lonardi S, **Wainberg ZA**, Ajani J, Chao J, Janjigian Y, Qin A, Singh J, Barlaskar F, Kawaguchi Y, Ku G. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. *Lancet Oncol.* 2023 Jul;24(7):744-756. doi: 10.1016/S1470-2045(23)00215-2. Epub 2023 Jun 14.
- Shitara K, Di Bartolomeo M, Mandala M, Ryu MH, Caglevic C, Olesinski T, Chung HC, Muro K, Goekkurt E, McDermott RS, Mansoor W, **Wainberg ZA**, Shih CS, Kobie J, Nebozhyn M, Cristescu R, Cao ZA, Loboda A, Özgüroğlu M. [Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial.](#) *Immunother Cancer.* 2023 Jun;11(6):e006920. doi: 10.1136/jitc-2023-006920.
- **Zev A Wainberg**, Davide Melisi, Teresa Macarulla, Roberto A Pazo Cid, Sreenivasa R Chandana, Christelle De La Fouchardière, Andrew Dean, Igor Kiss, Woo Jin Lee, Thorsten O Goetze, Eric Van Cutsem, Scott Paulson, Tanios Bekaii-Saab, Shubham Pant, Richard Hubner, Zhimin Xiao, Huanyu Chen, Fawzi Benzaghrou, Eileen M O'Reilly. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. *Lancet.* 2023 Oct 7;402(10409):1272-1281. doi: 10.1016/S0140-6736(23)01366-1. Epub 2023 Sep 11. PMID: 37708904.
- Tae Won Kim, Philippe L. Bedard, Patricia LoRusso, Michael S. Gordon, Johanna Bendell, Do-Youn Oh, Myung-Ju Ahn, Elena Garralda, Sandra P. D'Angelo, Jayesh Desai, F. Stephen Hodi, **Zev Wainberg**, Jean-Pierre Delord, Phillippe A. Cassier, Andres Cervantes, Marta Gil-Martin, Benjamin Wu, Namrata S. Patil, Yanling Jin, Tien Hoang, Diana Mendus, Xiaohui Wen, Raymond Meng & Byoung Chul Cho \*. First-in-human phase Ia/Ib study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors: dose-escalation and dose-expansion (Accepted at JAMA Oncology)
- Eric Van Cutsem, Rona Yaeger, Jean-Pierre Delord, Josep Tabernero, Lillian L. Siu, Michel Ducreux, Salvatore Siena, Elena Elez, Stefan Kasper, Thomas Zander, Neeltje Steeghs, Danielle Murphy, Michelle Edwards, and **Zev A. Wainberg**. A Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab in Patients with Mutant or Wild-Type RAS Metastatic Colorectal Cancer. *Oncologist.* 2023 Aug 19:oyad210. doi: 10.1093/oncolo/oyad210. Online ahead of print. PMID: 37597246.
- Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fernández MG, Li J, Lowery MA, Çil T, Cruz FM, Qin S, Luo S, Pan H, **Wainberg ZA**, Yin L, Bordia S, Bhagia P, Wyrwicz LS; KEYNOTE-859 investigators. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. *Lancet Oncol.* 2023 Nov;24(11):1181-1195. doi: 10.1016/S1470-2045(23)00515-6. Epub 2023 Oct 21. PMID: 37875143



# Seoul International Digestive Disease Symposium 2024

In Conjunction with the Annual Meeting of the Korean Society of Gastroenterology


April 20-21, 2024

Grand Walkerhill Seoul, Korea

*“Pioneering the future of digestive diseases”*



SIDDS 2024



SIDDS 2024 Secretariat

MediOffice | Tel : +82-2-459-8286 Fax : +82-2-459-8256 E-mail: [sidds2024@medioffice.or.kr](mailto:sidds2024@medioffice.or.kr)